ADA: Diabetes Collaborative Registry IDs Burden of Cardiac RiskLast Updated: June 14, 2016. The Diabetes Collaborative Registry provides information regarding the quality of diabetes mellitus care, according to research presented at the American Diabetes Association's 76th Scientific Sessions, held from June 10 to 14 in New Orleans.
TUESDAY, June 14, 2016 (HealthDay News) -- The Diabetes Collaborative Registry provides information regarding the quality of diabetes mellitus (DM) care, according to research presented at the American Diabetes Association's 76th Scientific Sessions, held from June 10 to 14 in New Orleans.
Suzanne V. Arnold, M.D., from the University of Missouri-Kansas City School of Medicine, and colleagues invited primary care, endocrinology, cardiology, and multispecialty practices to participate in the Diabetes Collaborative Registry, with data extracted continuously from electronic health records. The researchers note that 256 practices have enrolled in the Diabetes Collaborative Registry since 2015. Initial data for 812,037 patients showed a predominance of cardiovascular disease risk factors and complications; 87.6 percent had hypertension, 79.7 percent had dyslipidemia, and 58.7 percent had coronary artery disease.
The authors also assessed the average rate of adherence to seven DM quality metrics across 236 practices with 861,699 patients. The researchers found that the average adherence was 20 percent for glycated hemoglobin checked and ≤9 percent; 73 percent for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; 70 percent for nephropathy screening; 89 percent for blood pressure <140/90 mm Hg or on two or more antihypertensive medications; 85 percent for screening for smoking and encouraging smokers to stop; 11 percent for eye exam; and 1.2 percent for foot exam.
"Highlighting variability in diabetes care is one of the key objectives of the registry," Mikhail N. Kosiborod, M.D., steering committee chair of the Diabetes Collaborative Registry, said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim, both of which funded the registry.
|Previous: Midlife PSA Levels Predict Future Lethal Prostate Cancer||Next: Resident-on-Resident Aggression at Nursing Homes Not Uncommon|
Reader comments on this article are listed below. Review our comments policy.